Skip to Main Content
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Inside the Corner Office
    • Rising Stars Network
    • Celebrating 100 Years
      • New England Council Fellows Program
    • Sponsorship Opportunities
  • Contact
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Inside the Corner Office
    • Rising Stars Network
    • Celebrating 100 Years
      • New England Council Fellows Program
    • Sponsorship Opportunities
  • Contact

News

Jun 22, 2023Blog | Member News, Healthcare

Eli Lilly joins Verve Therapeutics for gene-editing project

Photo via Eli Lilly

New England Council member, Eli Lilly, is collaborating with Verve Therapeutics on a gene-editing program with a total value of $525 million. Eli Lilly will pay $60 million to use Verve’s gene-editing technology to target a cholesterol-carrying protein. The agreement also includes potential milestone payments of up to $465 million, as well as royalties for Verve. Verve plans to test Phase 1 clinical trials, with Eli Lilly handling clinical development, manufacturing, and commercialization.   

Verve Therapeutics, which focuses on eliminating cardiovascular disease associated with high cholesterol, emerged in 2019 with technology developed by Harvard scientists. The company went public in 2021 and has received investments from GV, Wellington Management Company, and Casdin Capital, as well as collaboration deals with Beam Therapeutics and Verily. Following the announcement of the collaboration, Verve’s shares rose more than 12%.  

The New England Council would like to congratulate Eli Lilly and Verve Therapeutics for this collaborative effort. 

Read more from the Boston Business Journal. 

Council Related News
Read Article Blog | Member News, Energy & Environment

Dominion Energy Charitable Foundation awards grants to 352 Nonprofits

Read Article Blog | Member News, Higher Education

University of New England announces partnership with Atlantic Hospitality to advance student careers

Read Article Blog | Member News, Higher Education

A study released by the CCIC reveals independent colleges are vital to the state’s economy

Read Article Blog | Member News, Energy & Environment

Unitil and Eversource Announce Water Utility Deals

Read Article Blog | Member News, Technology & Innovation

General Dynamics Electric Boat awarded $12.2 billion contract to boost shipbuilder pay and build two new submarines

View Related News

©2025 New England Council
All rights reserved.

Privacy Policy Website Design by Jackrabbit

Boston Office

98 North Washington Street
Suite 303
Boston, MA 02114

(617) 723-4009

necouncil@newenglandcouncil.com

Washington Office

1411 K Street, NW
Suite 700
Washington, D.C. 20005

(202) 547-0048

necouncil@newenglandcouncil.com

Website Design by Jackrabbit